http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Khalid Khadawardi (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
( Saeed Baradwan ),( Sahar Hassan Abdulghani ),( Mohammed Abuzaid ),( Khalid Khadawardi ),( Majed Saeed Alshahrani ),( Abdulrahman Al-matary ),( May A. Alrasheed ),( Najlaa Talat Miski ),( Aroob Abdul 대한산부인과학회 2021 Obstetrics & Gynecology Science Vol.64 No.6
To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that investigated the clinical benefits of 17-alpha hydroxyprogesterone caproate (17OHPC) in the prevention of recurrent preterm birth (PTB) among singleton pregnant women with a previous history of PTB. We searched four major databases up till April 2021 and assessed the risk of bias in the included studies. We meta-analyzed various maternal-neonatal endpoints (n=18) and pooled them as mean difference or risk ratio (RR) with 95% confidence interval (CI) using the random-effects model. Six RCTs met the inclusion criteria, comprising 2,573 patients (17OHPC=1,617, control=956). RCTs revealed an overall low risk of bias. The rates of PTB <35 weeks (n=5 RCTs; RR, 0.77; 95% CI, 0.63-0.93; P=0.008), PTB <32 weeks (n=3 RCTs; RR, 0.68; 95% CI, 0.51-0.91; P=0.009), neonates with low birth weight (<2.5 kg) at delivery (n=3 RCTs; RR, 0.63; 95% CI, 0.5-0.79; P<0.001), and neonatal death (n=4 RCTs; RR, 0.41; 95% CI, 0.20-0.84; P=0.02) were significantly reduced in the 17OHPC group compared with the control group. Moreover, 17OHPC treatment correlated with a significantly decreased rate of retinopathy (n=2 RCTs; RR, 0.42; 95% CI, 0.18-0.97; P=0.004). However, there were no significant differences in the rates of neonatal intensive care unit admission, cesarean delivery, and other pretermrelated complications between both the groups. Among singleton pregnant women with a prior history of PTB, 17OHPC may favorably decrease the risks of recurrent PTB and reduce the rate of neonatal death.
-
Saeed Baradwan,Abdulrahim Gari,Hussein Sabban,Majed Saeed Alshahrani,Khalid Khadawardi,Ibtihal Abdulaziz Bukhari,Abdullah Alyousef,Ahmed Abu-Zaid 대한산부인과학회 2024 Obstetrics & Gynecology Science Vol.67 No.2
This study aimed to review randomized controlled trials (RCTs) investigating the effects of dietary antioxidant supplements on the severity of endometriosis-related pain symptoms. The PubMed/Medline, Scopus, and Web of Science databases were searched until April 2022. Additionally, we manually searched the reference lists. Endpoints were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) in a random-effects model. The I2 statistic was used to assess heterogeneity. Ten RCTs were included in this meta-analysis. Overall, 10 studies were related to dysmenorrhea, four to dyspareunia, and four to pelvic pain. Antioxidants significantly reduced dysmenorrhea (SMD, -0.48; 95% CI, -0.82 to -0.13; I2=75.14%). In a subgroup analysis, a significant reduction of dysmenorrhea was observed only in a subset of trials that administered vitamin D (SMD, -0.59; 95% CI, -1.13 to -0.06; I2=69.59%) and melatonin (SMD, -1.40; 95% CI, -2.47 to -0.32; I2=79.15%). Meta-analysis results also suggested that antioxidant supplementation significantly improved pelvic pain (SMD, -1.51; 95% CI, -2.74 to -0.29; I2=93.96%), although they seem not to have a significant beneficial impact on the severity of dyspareunia. Dietary antioxidant supplementation seems to beneficially impact the severity of endometriosis-related dysmenorrhea (with an emphasis on vitamin D and melatonin) and pelvic pain. However, due to the relatively small sample size and high heterogeneity, the findings should be interpreted cautiously, and the importance of further well-designed clinical studies cannot be overstated. This study aimed to review randomized controlled trials (RCTs) investigating the effects of dietary antioxidant supplements on the severity of endometriosis-related pain symptoms. The PubMed/Medline, Scopus, and Web of Science databases were searched until April 2022. Additionally, we manually searched the reference lists. Endpoints were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) in a random-effects model. The I<sup>2</sup> statistic was used to assess heterogeneity. Ten RCTs were included in this meta-analysis. Overall, 10 studies were related to dysmenorrhea, four to dyspareunia, and four to pelvic pain. Antioxidants significantly reduced dysmenorrhea (SMD, -0.48; 95% CI, -0.82 to -0.13; I<sup>2</sup>=75.14%). In a subgroup analysis, a significant reduction of dysmenorrhea was observed only in a subset of trials that administered vitamin D (SMD, -0.59; 95% CI, -1.13 to -0.06; I<sup>2</sup>=69.59%) and melatonin (SMD, -1.40; 95% CI, -2.47 to -0.32; I<sup>2</sup>=79.15%). Meta-analysis results also suggested that antioxidant supplementation significantly improved pelvic pain (SMD, -1.51; 95% CI, -2.74 to -0.29; I<sup>2</sup>=93.96%), although they seem not to have a significant beneficial impact on the severity of dyspareunia. Dietary antioxidant supplementation seems to beneficially impact the severity of endometriosis-related dysmenorrhea (with an emphasis on vitamin D and melatonin) and pelvic pain. However, due to the relatively small sample size and high heterogeneity, the findings should be interpreted cautiously, and the importance of further well-designed clinical studies cannot be overstated.
-
Ahmed Abu-Zaid,Saeed Baradwan,Ehab Badghish,Rayan AlSghan,Ahmed Ghazi,Bayan Albouq,Khalid Khadawardi,Nora F AlNaim,Latifa F AlNaim,Meshael Fodaneel,Fatimah Shakir Abualsaud,Mohammed Ziad Jamjoom,Abdul 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.5
To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated the efficacyand safety of prophylactic tranexamic acid (TXA) versus a control (placebo or no treatment) during hysterectomy forbenign conditions. Six databases were screened from inception to January 23, 2022. Eligible studies were assessed forrisk of bias. Outcomes were summarized as weighted mean differences and risk ratios with 95% confidence intervalsin a random-effects model. Five studies, comprising six arms and 911 patients were included in the study. Two andthree studies had an overall unclear and low risk of bias, respectively. Estimated intraoperative blood loss, requirementfor postoperative blood transfusion, and requirement for intraoperative topical hemostatic agents were significantlyreduced in a prophylactic TXA group when compared with a control group. Moreover, postoperative hemoglobinlevel was significantly higher in the prophylactic TXA group than in the control group. Conversely, the frequencyof self-limiting nausea and vomiting was significantly higher in the prophylactic TXA group than in the control group. There were no significant differences between the groups in terms of surgery duration, hospital stay, and diarrhearate. All the RCTs reported no incidence of major adverse events in either group, such as mortality, thromboembolicevents, visual disturbances, or seizures. There was no publication bias for any outcome, and leave-one-out sensitivityanalyses demonstrated stability of the findings. Among patients who underwent hysterectomy for benign conditions,prophylactic TXA appeared largely safe and correlated with substantial reductions in estimated intraoperative bloodloss and related morbidities.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
